Search PubMed⌕ Search

Biomedical subjects

J J Keuning

Publications and source records attributed to J J Keuning.

35 records · Page 2Linked to original sources
PubMed1982

High dose cytosine arabinoside in the management of refractory acute leukaemia.

17 patients (age 15-58 years) with refractory acute leukaemia (14 AML, 3 ALL) were treated with high dose cytosine arabinoside (AraC) at a dose of 3000 mg/m2, twice daily for 6 d (13 patients with AraC alone, 4 patients with AraC and doxorubicin). 9 patients achieved complete remission (53%) and 2 a partial remission. Although sophisticated isolation and blood banking facilities are required during the pancytopenic period, the toxicity of this treatment was acceptable. Vomiting, headache, somnolence, fever, conjunctivitis and cardiac arrhythmias were found most frequently. The unexpected pulmonary failure in 3 patients was worrisome. The duration of remissions was from 1 to 12 months. Results obtained with high dose AraC are satisfactory and hold promise for the treatment of patients with previously untreated AML.

Adolescent↗
PubMed1977

Evidence for two series of B-cell antigens in man and their comparison with HLA-D.

Population and family studies of five sera with antibodies against B-cell determinants show an excellent fit of some of them with the HLA-D determinants, suggesting that the HLA-D determinants themselves or closely linked structures can be recognized by serology. One serum, Ag, might be coded for by a locus different from HLA-D, which could be located between HLA-A and -B. A two-color fluorescence test to detect B-cell antigens was used and found to save time and reagents and to give very good results.

B-Lymphocytes↗
PubMed1976

HLA-DW3 associated with coeliac disease.

28 patients with coeliac disease (C.D.) were typed for the HLA-A, -B, and -D loci by several techniques. It was found that C.D. is primarily associated with the DW3 determinant and only secondarily with HLA-B8. The previously described association with HLA-B8 is explained by linkage disequilibrium between HLA-B8 and DW3.

Adult↗
PubMed1976

B-cell antibodies, Ia-like determinants, and their relation to MLC determinants in man.

The HLA supergene is located in the 6th chromosome. Its position to the centromere and the position of a number of polymorphic isoenzymes has been elucidated. The HLA supergene codes not only for determinants present on all nucleated cells, but also for determinants present on B cells and absent from T cells and platelets. These determinants can be recognized by serology, and evidence is presented that some of them are coded for by a hither to unrecognized locus Ag, which is very closely linked to the MLC determinants of the D locus can be recognized with the help of the MLC test using unprimed cells, homozygous for the MLC determinants, so-called typing cells primed against one MLC determinant in the PLT test. So far, 8 MLC determinants have been recognized. Significant disease-association studies in different racial groups appear to be especially informative. They already indicate that the association found so far must rest on different mechanisms. Whether some of them could be caused by partial deficiency for one or more of the complement factors remains to be proven.

Animals↗
PubMed1975

The serological recognition of the human MLC determinants using a modified cytotoxicity technique.

A new approach which presumably recognizes MLC determinants (or at least structures closely linked to MLC and different from the FOUR, AJ and LA series determinants) by serology is described. As the test can be performed within 10 h it could be used to match cadaveric kidney donors for these MLC determinants. Perhaps even more important is the fact that the antibodies detected by this technique could be used to study the immunochemistry of a class of determinants differing from the well known SD determinants.

Antibodies, Anti-Idiotypic↗
PubMedDate not supplied

The impact of 5-FU-based bolus chemotherapy on survival in patients with advanced colorectal cancer.

BACKGROUND: An analysis was performed to evaluate whether bolus chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) improves survival for patients with advanced colorectal cancer (ACC). PATIENTS AND METHODS: Two groups of patients were selected from a database which included all patients with colorectal cancer treated in our hospital since 1984. The first group consisted of all patients with irresectable metastases diagnosed between January 1984 and December 1989, who had a performance status of 0 or 1, and were younger than 76 years old. The second group consisted of all patients with irresectable metastases--younger than 76 years old and with a performance status of 0 or 1--who were started on chemotherapy between January 1994 and December 1997. In the first period chemotherapy was never given and in the second period chemotherapy was given to all motivated patients. None of the patients had received a previous metastasectomy or isolated liver perfusion. For chemotherapy, age, location of the metastases, type of surgical intervention for the primary tumor, Hemoglobin, Lactate Dehydrogenase and Carcinoembryonic Antigen concentration we evaluated the relationship with survival. Variables which showed a significant relation with survival in the univariant analysis (logrank test, p < 0.05) were entered into a proportional hazards regression analysis. RESULTS: In the univariant analysis chemotherapy and location of metastases showed a significant relation with survival. The median survival was 11 months for patients who had received chemotherapy and 8 months for untreated patients (p = 0.009). Chemotherapy and location of metastases both retained their significance in a proportional hazards regression analysis. CONCLUSION: In our study group chemotherapy added 3 months to the median life expectancy for patients with ACC.

Aged↗